DLL3 (Delta-like protein 3) is a member of the Notch receptor ligand family that inhibits Notch signaling and is considered a predictive marker of sensitivity to platinum-based chemotherapy for LCNEC. The gene discussed is DLL3; the disease is large cell neuroendocrine carcinoma.